Gold prices slip lower; consolidating after recent gains
MOUNTAIN VIEW, Calif. - Iridex Corporation (NASDAQ:IRIX), a provider of laser-based medical systems for eye conditions, has completed a strategic investment deal with Novel Inspiration International Co., Ltd. The transaction, which closed today, resulted in $10 million in gross proceeds and includes an option for an additional $10 million for future growth. The deal comes at a crucial time for the company, which currently has a market capitalization of $16.8 million and is trading near its 52-week low of $0.96. According to InvestingPro analysis, the stock appears to be trading below its Fair Value.
The investment comprises $6 million in Series B Preferred Stock and $4 million in convertible notes, with the potential for an extra $10 million in notes convertible into Iridex common stock, depending on the company’s market performance. These convertible notes are set at a three-year term with a 12% interest rate, payable quarterly in common stock. The company maintains a moderate debt level with a debt-to-equity ratio of 1.87 and a current ratio of 1.54, indicating adequate short-term liquidity despite recent challenges.
Iridex CEO Patrick Mercer expressed optimism about the partnership with Novel, highlighting the opportunity to enhance their laser-based treatments, especially after recent changes in reimbursement policies for certain glaucoma surgeries. William Moore, a former board member and CEO of Iridex, facilitated the deal with Novel and will rejoin the Iridex board as part of the agreement.
The funds from this transaction have been allocated to repay a senior convertible promissory note and for general corporate purposes. Additionally, Iridex announced Romeo Dizon as the new Chief Financial Officer, succeeding Fuad Ahmad.
The company plans to release its Q4 and full-year 2024 financial results on March 27, 2025, and will hold a special call for investors in April prior to the ASCRS Annual Meeting.
This report is based on a press release statement from Iridex Corporation.
In other recent news, Iridex Corporation has released its preliminary unaudited financial results for the fourth quarter and full year ending December 28, 2024. The company reported that its fourth-quarter revenue is expected to be between $12.6 million and $12.7 million, slightly up from $12.5 million in the same quarter the previous year. However, the overall annual revenue is anticipated to decline to a range of $48.6 million to $48.7 million, compared to $51.9 million in 2023. Despite this decrease, Iridex saw an increase in sales of its Cyclo G6® Glaucoma Laser Systems, selling 47 units in the fourth quarter, up from 35 in the same period last year. The company remains focused on profitability, with President and CEO Patrick Mercer emphasizing the goal of achieving positive EBITDA results in the fourth quarter of 2024. Iridex is also engaged in strategic discussions with multiple parties regarding potential transactions to enhance shareholder value. The company has addressed recent stock volatility, stating that it is unaware of any significant corporate developments that would explain the fluctuations. Iridex plans to present its final fourth-quarter and full-year 2024 financial results during a conference call on March 27, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.